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Abstract
Background: Genomic sequencing technologies have made the possibility of popu-
lation screening for whole panels of genetic disorders more feasible than ever before. 
As one of the most common single gene disorders affecting the UK population, he-
mophilia is an attractive candidate to include on such screening panels. However, 
very little is known about views toward genetic screening amongst people with he-
mophilia or their family members, despite the potential for a wide range of impacts 
on them.
Methods: Twenty‐two in‐depth qualitative interviews were undertaken to explore 
the views of adults with hemophilia and their family members, recruited through the 
Haemophilia Society UK. These interviews were used to develop a survey, the 
Haemophilia Screening Survey (UK), which was distributed in paper and online for-
mat through the support group, receiving 327 returns between January and June 
2018.
Results: Fifty‐seven per cent of the sample supported preconception carrier screen-
ing of the population for hemophilia, and 59% supported prenatal carrier screening. 
Key reasons for support included a desire to reduce pregnancy terminations and in-
crease awareness of hemophilia. Despite support for screening however, 90% of the 
sample disagreed with pregnancy terminations for hemophilia.
Conclusions: Families and adults living with hemophilia are more supportive of 
screening for information and preparation purposes than to prevent boys with hemo-
philia from being born. A distinction was made between preventing the disease and 
preventing the lives of people with it, with support shown for the use of screening to 
achieve the former, but not at the expense of the latter.
K E Y W O R D S
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1 |  INTRODUCTION
As the capacities of genomic technologies continue to ex-
pand and become more efficient, genomic information is 
more accessible to members of the public than ever before. 
Within the UK, the Genomics England initiative, the 100,000 
Genomes Project, highlights the high position of population 
genomics on the public agenda (Davies, 2016) and suggests 
a future in which population carrier screening using genomic 
sequencing techniques (potentially also accompanied by ge-
nome editing) are an accepted and widely used component of 
mainstream reproductive healthcare. Supporters of expansive 
carrier screening for rare genetic diseases have highlighted 
the significant risk that these disorders collectively pose to 
the public's health. Whilst individually rare, their combined 
incidence is comparable to that of Down Syndrome—a condi-
tion routinely screened for across the globe (Archibald et al., 
2017). Furthermore, it has been argued that the introduction 
of population carrier screening would expand the reproduc-
tive options of carrier parents (Human Genetics Commission, 
2011). For example, it would allow them the option of avoid-
ing the birth of an affected child altogether. Indeed, without 
pre‐conception or prenatal screening, the birth of an affected 
child is typically the most common route by which carrier 
parents discover their status. When preconception carrier 
screening is implemented, however, carrier parents may 
choose to access other technologies, such as pre‐implanta-
tion genetic diagnosis for use in their very first pregnancy 
to ensure the birth of an unaffected embryo. In addition, the 
potential for negative health implications associated with car-
rier status (e.g., in relation to hemophilia, thalassemia, sickle 
cell, and fragile x syndrome) are also being increasingly rec-
ognized, suggesting that carrier screening has wider health 
implications that go beyond the domain or reproduction 
(Abdul‐Kadir, Davies, Halimeh, & Chi, 2013). Despite these 
potential benefits, however, the acceptability of population 
carrier screens to both the general public, and, more specif-
ically the communities already living with genetic diseases, 
has been relatively under‐explored, although this body of 
literature is emerging (Archibald et al., 2013; Henneman et 
al., 2001; McClaren, Delatycki, Collins, Metcalfe, & Aitken, 
2008; Roadhouse et al., 2018). This under‐representation of 
families living with genetic diseases in debates around ge-
netic screening and selective reproduction is particularly 
striking as genetic screening would likely have implications 
for such families beyond those anticipated for the general 
public (Boardman & Hale, 2018). Such implications may in-
clude an increase in social stigmatization of those living with 
screened‐for conditions (as the public profile of the disorder 
shifts to a “preventable” disease), the potential for reductions 
in funding for research into treatments and the loss of peer‐
to‐peer support as the incidence of a condition declines over 
time (Nuffield Council on Bioethics, 2018).
Previous research on attitudes toward screening and se-
lective reproduction has been somewhat contradictory. 
Some studies have revealed widespread support for selec-
tive reproduction amongst affected families and adults (e.g., 
Chen & Schiffman, 2000; Conway, Allenby, & Pond, 1994; 
Janssens et al., 2016; Potrata, McKibbin, Lim, & Hewison, 
2014), whilst more recent research points to ambivalence 
and conflict (Maxwell et al., 2011), and sometimes outright 
rejection of the notion of screening on principle (Barter, 
Hastings, Williams, & Huws, 2016; Boardman & Hale, 2018; 
Roadhouse et al., 2018). Concerns have been expressed about 
the loss of (potentially) high quality life in spite of genetic 
disease, the implied implicit judgement on the value of life 
with disability and disapproval of the redirection of resources 
away from social and environmental barrier removal and to-
ward the medical elimination of the condition (Boardman 
& Hale, 2018; Middleton, Hewison, & Mueller, 1998; 
Roadhouse et al., 2018).
However, the diversity of views expressed and the sheer 
heterogeneity of lives affected by genetic disease—not 
only across diagnostic boundaries, but also within them 
(Boardman, Young, & Griffiths, 2016)—suggest that further 
research is required to better understand the perspectives of 
families and adults living with genetic disease and the associ-
ated factors that lend themselves toward either the support or 
nonsupport of genetic intervention in reproduction.
Drawing on a previous study of the views of families living 
with the neuromuscular disorder Spinal Muscular Atrophy 
(see Boardman et al., 2016), this exploratory analysis exam-
ines the reproductive views, decisions, and attitudes of fami-
lies and adults living with hemophilia. It is only through such 
an understanding that the full range of possible impacts of 
genetic carrier screening for conditions such as hemophilia 
can be anticipated, and their relevance to the implementation 
of future programmes considered.
1.1 | Hemophilia
Hemophilia is a rare, X‐linked blood clotting disorder typi-
cally affecting males (with female carriers) that causes exces-
sive and prolonged bleeding. In some circumstances, females 
can be affected by hemophilia if both of their parents are 
homozygous for the mutation (i.e., they carry the same mu-
tation), however this is considered very rare. Children born 
with hemophilia today can reasonably expect a normal or 
near‐normal lifespan (Haemophilia Society, 2003), although 
this varies significantly across the developing world (Ghosh, 
Shetty, Pawar, & Mohanty, 2002). Hemophilia A is the most 
severe and most common form of the disorder, accounting for 
around 70% of all diagnoses (Haemophilia Society, 2003). 
People with hemophilia A are particularly vulnerable to in-
jury and can experience spontaneous internal bleeds (often 
into joints) leading to acute pain and long‐term disability. 
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The most common cause of hemophilia‐related deaths are 
due to intracranial bleeds.
Hemophilia B is generally understood to be a less severe 
form of the disease, but for individuals with hemophilia 
B, spontaneous and internal bleeds can affect daily living. 
Treatment focuses primarily on replacing lost blood plasma 
and the administration of recombinant concentrates to substi-
tute the absent clotting factor. More recently, the introduction 
of prophylactic IV therapies have been proven effective at 
preventing bleeds in those with hemophilia A. The admin-
istration of contaminated blood products to people with he-
mophilia throughout the 1980s, however, has also led to the 
development of substantial co‐morbidities in older men with 
hemophilia (typically hepatitis B/C and HIV), as well as in-
creased social stigma for many people living with hemophilia 
in the UK (Barlow, Stapley, & Ellard, 2007).
1.2 | Genetic testing for hemophilia
Prenatal genetic diagnosis for pregnant women already 
known to be carriers of hemophilia became available dur-
ing the 1970s using analysis of fetal blood at 18–20 weeks’ 
gestation (Mårtensson, Tedgård, & Ljung, 2014), and pre‐im-
plantation genetic diagnosis (which involves the creation of 
embryos through IVF and then testing them for hemophilia 
prior to implantation) became available to hemophilia carriers 
in the UK in 2004. Both of these forms of testing, however, 
are only available to families already at risk of having a child 
with hemophilia (not the general population), and typically 
only those living with “severe” forms of the condition (Hill, 
Compton, Lewis, Skirton, & Chitty, 2012). Furthermore, the 
recent introduction of NIPT (Non‐Invasive Prenatal Testing) 
within NHS healthcare, is also likely to contribute to the de-
clining use of invasive prenatal testing for hemophilia. As 
NIPT can now be used to accurately determine fetal sex early 
in pregnancy, the unnecessary testing of female fetuses is 
gradually being eliminated (Hill et al., 2012).
1.3 | Testing and screening: The views of 
families and adults with hemophilia
Despite hemophilia being the most common inherited blood 
disorder, no previous studies exist that explore the views of 
both people with hemophilia and their families toward pop-
ulation carrier screening. This is in spite of the increasing 
recognition of the health implications of hemophilia carrier 
status (Hooper, Miller, & Key, 2010), and the rising health-
care costs associated with its management as more sophisti-
cated treatments are developed, and adults with hemophilia 
live increasingly long lifespans (Tsai et al., 2013). Where 
the views of the general public toward hemophilia screening 
have been considered, however, strong support for screen-
ing, and a greater willingness (than hemophilia carriers) to 
terminate a pregnancy affected by hemophilia have been ob-
served, although there remains a notable lack of evidence in 
this area (Tsai et al., 2013, p. 724).
Indeed, the majority of previous research studies that have 
been conducted on uses of, and attitudes toward, genetic test-
ing for hemophilia have all tended to focus on their use within 
already affected families, rather than by the general population. 
This research has shown that whilst there is generally great 
enthusiasm for the carrier testing of female relatives (often at 
young ages) (Dunn, Miller, Griffioen, & Lee, 2008; Thomas 
et al., 2007), that attitudes toward pregnancy termination for 
hemophilia produce far more mixed results (Varekamp et al., 
1990; Varekamp, Suurmeuer, Rosendaal, & Brocker‐Vriends, 
1993). Indeed, a survey of 207 obligate and potential carriers 
in the Netherlands by Balak et al. (2012) suggested that there 
is broad support for the use of prenatal diagnosis (54% of their 
sample had accessed it) with 82% of identified affected pregnan-
cies being terminated. However, evidence from other surveys of 
carriers contradict Balak et al.'s (2012) findings, with reports of 
far lower levels of acceptance of both prenatal testing, but also 
pregnancy termination (e.g., Kadir et al., 2000; Mårtensson et 
al., 2014; Dunn et al., 2008; Tsai et al., 2013; Varekamp et al., 
1990; Ratna, Lehesjoki, Peippo, & Kaariainen, 1994; Kraus & 
Brettler, 1988). Varekamp et al.'s (1990) Dutch study, for exam-
ple, revealed that only 31% of the 549 female carriers they sur-
veyed would consider prenatal testing and selective termination 
for hemophilia, whilst Kadir's more recent (2000) UK‐based 
study of 197 female carriers produced a similar result, show-
ing that only 27% of affected pregnancies (identified through 
prenatal testing) were terminated on the grounds of hemophilia 
(in spite of broad support for diagnostic testing). For surveys 
conducted by Kraus and Brettler (1988) and Ratna et al (1994), 
these figures were even lower, at 17% and 16% acceptance of 
testing and termination amongst female carriers respectively.
Key reasons for supporting and accessing prenatal diagnosis 
and selective termination for hemophilia have been identified as 
relating to the severity of the hemophilia in the family, liberal 
attitudes toward pregnancy termination and being of older age 
(Balak et al., 2012). Key reasons for non‐support/non‐use of 
prenatal testing and selective termination, however, include the 
acceptance of hemophilia as a “liveable” condition compatible 
with a good quality of life, fear of fetal loss associated with an 
invasive test, as well as religious objections to the interruption 
of pregnancy (Balak et al., 2012; Kadir et al., 2000; Kraus & 
Brettler, 1988; Ratna et al., 1994; Varekamp et al., 1990).
It is noteworthy, however, that such surveys have tended 
to focus exclusively on the views and decisions of female 
hemophilia carriers, to the exclusion of adult males with 
hemophilia themselves. Whilst this exclusion may be jus-
tified on grounds that it is carrier women (not men with 
hemophilia) to whom the technologies are offered, there 
are nevertheless compelling reasons to consider the views 
of genetically disabled adults in such debates, particularly 
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given the range of possible negative impacts for them if 
mass screening were to be introduced. Where men with 
hemophilia have been included in research studies on this 
topic, there is some (limited) evidence to suggest that 
they hold more favorable attitudes toward hemophilia pre-
vention than any other stakeholder group (Thomas et al., 
2007, p. 637), however evidence on this remains scant.
To address this identified gap in the literature, this paper 
presents a mixed methods sequential analysis (Creswell & 
Plano Clark, 2006) of 22 in‐depth qualitative interviews 
and a national UK survey (n = 327) conducted with fami-
lies and adults affected by hemophilia. The study explores 
their attitudes toward, and actual/anticipated uses of, pre-
natal testing, carrier testing, and selective pregnancy ter-
mination for hemophilia, but also their perceptions of the 
expansion of genetic screening for hemophilia beyond af-
fected families to the general population. In so‐doing, this 
paper offers a contribution to the growing body of litera-
ture exploring the impacts of genomic medicine for those 
already living with genetic disease.
2 |  METHODS
2.1 | Ethical compliance
Ethical approval was granted from the Biomedical and 
Scientific Research Ethics Committee for the qualita-
tive interviews on 21/02/17 (REGO‐2017‐1910), and 
for the Hemophilia Screening Survey (UK) on 17/11/17 
(REGO‐2017‐1910 AM02).
2.2 | Data collection methods
This study involved the collection of both qualitative and 
quantitative data using an exploratory sequential mixed 
methods design. The data were collected between April 2017 
and June 2018 through the use of exploratory in‐depth in-
terviews (phase I), a quantitative survey (phase II), and an 
integrated mixed methods analysis (phase III).
2.2.1 | Qualitative interviews: Phase I
In order to explore the perspectives of families and adults liv-
ing with hemophilia on screening and reproductive genetics, 
a call for participants was placed in the Haemophilia Society's 
newsletters, website, and social media accounts. People with 
different types of bleeding disorder were initially included 
in this exploratory phase of the research. This strategy led to 
the successful recruitment of 22 participants (15 females and 
7 males), with interviews taking place between April 2017 
and March 2018 (see Table 1 for a breakdown of qualitative 
interview participants). Ten of the participants had a bleed-
ing disorder themselves (six males with hemophilia, one 
male with factor XII deficiency, and three females with Von 
Willebrands disease), and participants were geographically 
dispersed throughout the UK. Given this dispersion, partici-
pants were given a choice of interview method: telephone, 
face‐to‐face, or email. This led to four interviews taking 
place face‐to‐face (three in the participant's home and one 
at the University) and 18 interviews were conducted by tele-
phone. The average length of interview (for both face‐to‐face 
and telephone interviews combined) was 47 min.
Within interviews, participants were asked about their expe-
riences of living with hemophilia, its impact on daily life, their 
views on reproduction in the context of genetic technologies, as 
well as their perceptions of the possibility of population carrier 
screening for hemophilia. The interviews were all recorded and 
transcribed verbatim before being transferred to Nvivo 11 qual-
itative data analysis software for analysis. A constructivist ap-
proach to grounded theory data analysis was used which involved 
initial “open coding” before more hierarchical coding. A process 
of coding, refinement of concepts through analysis meetings and 
reference to the literature, followed by re‐coding was carried out 
over a period of three months until “data saturation” (i.e., no new 
themes were emerging) had occurred (Glaser & Strauss, 1967).
2.2.2 | Hemophilia Screening Survey (UK): 
Phase II
Following analysis of the qualitative data, and in reference to 
a previously developed survey (Boardman et al., 2016), the 
Haemophilia Screening Survey (UK) was developed in order 
to measure the prevalence of ideas about screening expressed 
in the qualitative interviews on a larger scale. Retaining the 
same basic structure of a previously administered survey, the 
SMA Screening Survey (UK) (Boardman et al., 2016), this 
new survey was tailored to the ideas expressed in the qualita-
tive interviews, as well as factors unique to hemophilia, such as 
T A B L E  1  Qualitative interview participant characteristics and interview type
Participants Numbers
Gender Interview type
Female Male Face‐to‐face Telephone
Diagnosed with hemophilia/VWB 10 3 8 2 8
Family member of person diagnosed with hemophilia 12 11 0 2 10
Totals 22 14 8 4 18
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questions about treatment and exposure to contaminated blood. 
Questions designed to capture demographic information (such 
as educational attainment, religious faith, and ethnicity) were 
either directly replicated from, or appear as modified versions 
of, questions included in the 2011 UK Census survey. Within 
the survey, participants were asked about their support for 
two different types of screening programme: Preconception 
genetic screening (PCGS), a programme to identify carriers 
of hemophilia before a pregnancy is established and prenatal 
genetic screening (PNGS) to identify carriers (and potentially 
also affected foetuses) during pregnancy.
As well as the initial qualitative work, the survey was 
passed through an expert panel for feedback and cognitive 
interviewing before distribution. Cognitive interviewing 
is a widely used technique that uses in‐depth interviewing 
techniques in order to explore the mental processes that 
participants use to answer survey questions (Willis, 2005). 
The expert panel was made up of three people living with 
hemophilia in their family, two staff members of the UK 
Haemophilia Society and a hemophilia specialist nurse.
Survey data collection was carried out over a period of six 
months, between January and June 2018. Participants were in-
vited to complete it if they were aged over 18 and either had 
hemophilia themselves or had at least one diagnosis of hemo-
philia in their family. No restrictions were placed on the na-
ture of the familial relationship, for example, step, adopted and 
fostered family members were all included as the social rela-
tionship to the person with haemophilia was considered as im-
portant as the biological relationship in determining screening 
attitudes. Including various family members in the study also 
enabled an examination of the effect on reproductive attitudes 
that differing levels of proximity to hemophilia had.
A paper version of the survey was mailed to all house-
holds known to the Haemophilia Society UK, and an online 
version was also made available and distributed through the 
Haemophilia Society's online networks. A link to the survey 
was also made available through the research project's website 
and Twitter/Facebook feeds. Participants were encouraged to 
distribute the survey to interested family/friends affected by 
hemophilia, and postal survey returns were all processed using 
data scanning technology to reduce human error.
2.3 | Survey data stratification and 
statistical analysis
Responses to each question were stratified as follows: gender 
(Male 1 vs. Female 0); age (35‐45 1 vs. other 0); qualifica-
tions (degree or above (1) vs. other (0)); religious (yes (1) vs. 
no (0)); do you have children (yes (1) vs. no (0)); relation-
ship to hemophilia (adults with disease (AWD) (1) vs. family 
(0)); type of hemophilia associated with your family (A (1) 
or B (0)). For all questions regarding screening answers were 
stratified as either agree/strongly agree (1) or other (0). This 
was done because it allowed the simplest way of assessing 
the positive views of respondents.
The attitudes of families and adults with hemophilia to-
ward PCGS and PNGS were compared to determine if there 
were any statistical differences. The following sub‐group 
analyses were performed: All responders were analyzed col-
lectively to identify any overriding trends (all responders). 
Responses from families (all) and AwD (all) were compared 
to determine if living the disease altered. Sub‐analyses on 
responders associated with hemophilia A and B were then 
performed: (a) responses from families associated with he-
mophilia A were compared with responses from families 
with hemophilia B; (b) responses from adults with hemo-
philia A were compared with responses from adults with 
hemophilia B; (c) responses from families associated with 
hemophilia A were compared with responses from adults 
with hemophilia A; and (d) responses from families associ-
ated with hemophilia B were compared with responses from 
adults with hemophilia B.
In each of the sub‐group analyses, the individual questions 
were assessed and then responses correlated against support 
for screening. For each question the number of “agree” versus 
“other” responses were reported and statistical differences 
between the subgroups were assessed using a chi‐squared 
analysis (Graphpad Prism software, v6).
2.3.1 | Integrated mixed methods analysis: 
Phase III
Following the qualitative and quantitative data analysis, 
the qualitative data were returned to in order to further 
interrogate the findings. Statistically significant findings 
from the survey were cross‐referenced with related themes 
from the qualitative dataset to explore possible reasons 
for the finding. For example, the finding that the major-
ity of the survey participants agreed that hemophilia can 
be compatible with a good quality of life was interpreted 
through the qualitative data surrounding day‐to‐day living 
with hemophilia. This technique of returning to the quali-
tative dataset following quantitative analysis is particu-
larly well suited to the identification of contradictions and 
nuances within the data (Creswell & Plano Clark, 2006), 
as well as to offer more in‐depth explanations for unu-
sual or unexpected findings. For a topic area as complex 
as screening, this technique proved particularly useful in 
both explaining and illustrating the key findings of the 
project. Qualitative excerpts chosen for inclusion in this 
paper were selected from the analysis of both phases I and 
III, and on the basis that they particularly eloquently or 
clearly reflect a theme that was significant to the overall 
analysis.
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3 |  RESULTS
In total, 22 participants took part in an in‐depth qualitative in-
terview, and 327 returned the Haemophilia Screening Survey 
(UK).
3.1 | Quantitative data
3.1.1 | Cohort descriptive characteristics
Of the 327 participants, 148 were family members of people 
with hemophilia (75.7%) and 179 had hemophilia themselves 
(24.3%; Table 2). A total of 173/327 (53%) participants were 
male, 85% of whom had hemophilia (Table 2). The majority of 
participants were over the age of 35 (85%), were not educated 
to degree level (57%), were religious (56%), and had children 
(77%) (Table 2). Most participants were associate with hemo-
philia A 271/327 (83%) rather than hemophilia B. Eighty‐six 
per cent of family members (127/148) (86%) were associated 
with type A and 146/179 (82%) of adults with hemophilia had 
been diagnosed with this form of the condition (Table 2).
3.1.2 | Preconception genetic screening
Overall, 57% of survey participants were in favor of PCGS 
and there was no statistical difference in the levels of sup-
port between families and adults with disease (57% vs. 56%; 
p = 0.82) (Tables 3 and 4). The level of support was similar 
in all analyzed subgroups: (a) families associated with he-
mophilia A versus families associated with hemophilia B 
(57% vs. 62%, p = 0.65); (b) adults with hemophilia A versus 
adults with hemophilia B (56% vs. 55%, p = 0.86); (c) fami-
lies associated with hemophilia A versus adults with hemo-
philia A (57% vs. 56%, p = 0.99); and (d) families associated 
with hemophilia B versus adults with hemophilia B (62% vs. 
55%, p = 0.77) (Tables 3 and 4).
T A B L E  2  Characteristics and demographics of survey responders. Demographics are shown for all responders (n = 327), responders 
associated with hemophilia families (families; n = 148), and individuals with hemophilia (adults with disease; n = 179)
Characteristic
All responders 
(n = 327) Families (n = 148)
Adults with disease 
(n = 179) p‐Value*
Gender—no. (%)    <0.0001
Male 173 (53%) 21 (14%) 152 (85%)  
Female 154 (47%) 127 (86%) 27 (15%)  
Age (years)    0.0002
18−25 11 (3%) 1 (1%) 10 (6%)  
26−34 38 (12%) 22 (15%) 16 (9%)  
35−45 68 (21%) 45 (30%) 23 (13%)  
46−55 60 (18%) 21 (14%) 39 (22%)  
56−65 65 (20%) 30 (20%) 35 (19%)  
>65 85 (26%) 29 (20%) 56 (31%)  
Qualifications    0.19
Degree or higher 142 (43%) 70 (47%) 72 (40%)  
Other/none 185 (57%) 78 (53%) 107 (60%)  
Religious    0.46
Yes 183 (56%) 88 (60%) 95 (53%)  
No 130 (40%) 55 (37%) 75 (42%)  
Prefer not to say 14 (4%) 5 (3%) 9 (5%)  
Parents    <0.0001
Yes 253 (77%) 135 (91%) 118 (66%)  
No 73 (22%) 12 (8%) 61 (24%)  
Prefer not to say 1 (1%) 0   
Type of hemophilia    0.31
Hemophilia A 273 (83%) 127 (86%) 146 (82%)  
Hemophilia B 54 (17%) 21 (14%) 33 (18%)  
Notes. Response distributions were compared between families and adults with disease and significant differences were assessed using chi‐squared analysis (p‐value).
*Significant differences are in italics (p < 0.05). 
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The main reasons participants supported PCGS were be-
cause it would reduce the number of terminations (all: 61%, 
Families: 63%, AwD: 60%; Tables 3 and 4) and that it would 
raise awareness of hemophilia in the general population (all: 
76%, Families: 76%, AwD: 77%; Tables 3 and 4). Again, 
there was no significant difference in responses between any 
of subgroups for these two questions (Tables 3 and 4).
Most of the responders did not agree that carrier screening 
and PCGS would alter people's choice in reproductive partner 
(all: 37%, Families: 35%, AwD: 39%; Tables 3 and 4) or that 
PCGS was a form of social engineering (all: 35%, Families: 
32%, AwD: 39%; Tables 3 and 4). In addition, most partici-
pants did not believe carrier screening/PCGS would lead to 
stigmatization of carriers (all: 39%, Families: 36%, AwD: 
41%; Tables 3 and 4); however, a higher percentage of adults 
with hemophilia A than adults with hemophilia B thought 
carrier stigmatization was an issue (45% vs. 24%, p = 0.03; 
Tables 3 and 4). This was the only significant difference 
identified between any of the subgroups for PCGS questions, 
which highlights the agreement between the different groups.
3.1.3 | Prenatal genetic screening
Overall, 59% of survey participants were in favor of PNGS 
and there was no statistical difference in the levels of sup-
port between families and adults with disease (60% vs. 58%; 
p = 0.73) (Tables 5 and 6). The level of support was similar 
in all analyzed subgroups: (a) families associated with he-
mophilia A versus families associated with hemophilia B 
(60% vs. 62%, p = 0.85); (b) adults with hemophilia A versus 
adults with hemophilia B (58% vs. 58%, p = 0.94); (c) fami-
lies associated with hemophilia A versus adults with hemo-
philia A (60% vs. 58%, p = 0.81); and (d) families associated 
with hemophilia B versus adults with hemophilia B (62% vs. 
58%, p = 0.78) (Tables 5 and 6).
The main reasons participants supported PNGS were be-
cause it would allow everyone to make informed decisions 
about the pregnancy (all: 67%, Families: 61%, AwD: 71%; 
Tables 5 and 6) and that it would raise awareness of hemo-
philia in the general population (all: 74%, Families: 73%, 
AwD: 74%; Tables 5 and 6). Although there was no signif-
icant difference between the sub‐groups for either of these 
questions, the difference between families (all) and adults 
with hemophilia (all) was approaching significance (61% vs. 
71%, p = 0.07; Tables 5 and 6).
Most of the participants did not agree that PNGS would 
prevent unnecessary suffering (all: 35%, Families: 32%, 
AwD: 37%; Tables 5 and 6) or that it would be hard for 
people to refuse screening (all: 31%, Families: 32%, AwD: 
31%; Tables 5 and 6). Interestingly, however, most partici-
pants did not think it would be a loss to society to have fewer 
people with hemophilia being born, although the difference 
between families (all) and adults with hemophilia (all) was Q
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on
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approaching significance (all: 39%, Families: 45%, AwD: 
35%; Families (all) vs. AwD (all), p = 0.08; Tables 5 and 6).
Screening is principally about providing information to ex-
pecting parents; what parents subsequently decide to do with 
this information is an individual decision. With this in mind, two 
questions were specifically set: (a) whether termination is un-
fortunately necessary to eliminate hemophilia; and (b) whether 
PNGS was important to prepare parents for the birth of an af-
fected child. Results categorically identify that in this cohort, 
participants believe that PNGS is important for preparation 
(all: 69%, Families: 74%, AwD: 66%), with far fewer believing 
termination was necessary to eliminate the disease (all: 10%, 
Families: 8%, AwD: 12%) (Tables 5 and 6). Again, although 
there were no significant differences between the sub‐groups, it 
is important to note that fewer adults with hemophilia A thought 
PNGS was important to allow parents to prepare than hemo-
philia A families (63% vs. 72%, p = 0.08; Tables 5 and 6).
3.2 | Qualitative data
Our quantitative data suggest that whilst hemophilia‐affected 
families and adults broadly support PCGS and PNGS, that 
support for pregnancy termination where hemophilia is de-
tected was nevertheless strikingly low (Tables 3‒6). In order 
to further explore this finding, the qualitative data were re-
turned to in phase III of the study in order to explore possible 
reasons for this seeming contradiction.
In total, 22 participants completed an in‐depth qualita-
tive interview between April 2017 and March 2018. Ten of 
the participants had hemophilia themselves (three had von 
Willebrand's Disease and six had hemophilia and one factor 
XIII deficiency), with the remaining 12 being the female 
family members (daughters/mothers/sisters/wives/grand-
mothers/aunts) of someone with a hemophilia (see Table 
7). Thirteen of the 22 participants (59% of the sample) had 
at least two diagnoses of hemophilia in their family, and 
out of the 10 individuals who had hemophilia themselves, 
four also had (or experienced the loss of) an affected rela-
tive, highlighting the relatively high degree of recurrence 
of hemophilia within families. The majority (68%) of the 
sample was female (n = 15), with all seven male partici-
pants having hemophilia themselves (no unaffected male 
family members responded). The age range of the sample 
was 26–83.
T A B L E  4  Response summaries for questions assessing views on preconception genetic screening (PCGS). A) Response breakdowns are 
shown for family sub‐groups (all, hemophilia A and hemophilia B) and adults with disease sub‐groups (all, hemophilia A and hemophilia B). 
Responses for each question were stratified as “agree” versus “other” (other=disagree and neither disagree nor agree)
Question
F vs. AwD (all) F (Hem A vs. B) AwD (Hem A vs. B)
Hem A 
(F vs. 
AwD)
Hem B 
(F vs. 
AwD)
p‐Value
Identifying carriers of hemophilia before a 
pregnancy is conceived will affect people's 
choice of reproductive partner (the person you 
choose to have a baby with)
0.56 0.49 0.91 0.81 0.56
Identifying carriers of hemophilia in the general 
population will lead to carriers feeling 
stigmatized or different
0.49 0.41 0.03 0.27 0.75
Identifying carriers of hemophilia before a 
pregnancy is established is a good thing, as it 
will reduce the number of terminations due to 
hemophilia
0.64 0.37 0.49 0.99 0.26
Identifying carriers of hemophilia in the general 
population will increase awareness of Bleeding 
Disorder as a condition
0.99 0.27 0.73 0.88 0.72
People from the general population won’t be 
interested in finding out their carrier status for 
hemophilia as they won’t think its relevant to 
them
0.14 0.71 0.87 0.22 0.41
Preconception genetic screening is a form of 
“social engineering” (a way of controlling the 
genetic make‐up of the population)
0.24 0.39 0.36 0.52 0.15
I would support a preconception genetic 
screening programme for hemophilia
0.82 0.65 0.86 0.99 0.77
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Within their interviews, participants were asked to talk 
about their stories with hemophilia, its impact on their day‐
to‐day lives, as well as their hopes and expectations for the 
future. Fourteen of the participants reported being very fa-
miliar with the condition, having grown up around people 
with hemophilia (either because they had one themselves, 
or a member of their immediate family did), whereas the re-
maining eight participants first encountered hemophilia later 
in life, one through having a delayed onset of hemophilia 
(John) and the remainder through either having an affected 
son (Sophie; Karen; Jenny; Chloe; Harriet) or marrying a 
man diagnosed with hemophilia (two participants—Sarah; 
Valerie) (see Table 7). However, even for these lesser expe-
rienced participants, there was only one participant (Karen, 
whose son with hemophilia was only eight months of age at 
the time of interview) who did not have at least five years of 
prior experience of living with hemophilia in some capacity 
before their interview.
It has been suggested in the literature (Varekamp et al., 
1990) that unlike the trend observed with other X‐linked 
disorders such as fragile X syndrome (Kay & Kingston, 
2002), that proximity to, and amount of contact with hemo-
philia impacts attitudes toward the disorder, with increased 
contact correlating with more positive and accepting atti-
tudes about having a child with hemophilia oneself (Thomas 
et al., 2007). This finding was borne out in our qualitative 
data, particularly among women who had grown up with 
hemophilia.
Rosie was 38 at the time of her interview, working part‐
time in a management job and had two sons, Jacob and 
Harvey aged 4 and 6, respectively. Rosie was an obligate 
hemophilia carrier, being the daughter of Roy, diagnosed 
with hemophilia in early childhood, along with his brother 
Les. Rosie described her decision to refuse diagnostic test-
ing during both of her pregnancies, believing that hemo-
philia is insufficient reason to terminate a pregnancy, and 
Harvey, her eldest child, was diagnosed with hemophilia 
shortly after birth. Given her family's history, Rosie re-
ported feeling somewhat prepared for what life with hemo-
philia would be like;
I think we were really well prepared because, 
you know, we knew it was a 50% chance. I'd 
done a lot of reading to sort of inform myself 
of like where things are, you know, where the 
treatments are at now. So I was kind of sure in 
my own mind what was going to be going on. 
We've taken the view all along, this is not a life 
limiting condition, in either sense of the word, 
and you know, my dad, although his health has 
suffered has, you know, he's rally driving, he's 
done sea sailing he's, you know, this isn't some-
thing that makes you stop living your life, it will 
be a part of our boy….. but for Harvey, it's 5% 
of who he is. The fact that he's like really sensi-
tive and can be really stroppy is a bigger part of 
his personality and who is than the fact that his 
blood's a bit dodgy.
By using her father and uncle's experiences as her point 
of reference, Rosie was able to view Harvey's hemophilia 
as something that her family—already well versed in deal-
ing with the condition—would take in their stride. Indeed, 
by comparing current hemophilia treatments to the treat-
ments Roy and Les received as children (which included 
the accidental transmission of Hepatitis C to them both 
in early adulthood), Rosie described hemophilia as being 
“much less of a big deal” now than it was when her father 
and uncle were young. Indeed, her insights into their early 
experiences of treatment likely generated and facilitated a 
more positive view of current hemophilia treatments than 
she may have had without this prior knowledge. It was due 
to this availability of prophylaxis therapy that, Harvey, al-
though six, had yet to experience a significant bleed and 
Rosie described his avid participation in physical activities 
including Taekwondo and trampolining—activities that 
simply would have been too risky for him to participate in 
prior to the commencement of prophylaxis.
For Rosie, as well as the majority of the other 21 par-
ticipants, this view of hemophilia as a condition that is not 
“life limiting” translated into conflicted and sometimes neg-
ative attitudes toward a population screening programme for 
it, particularly on account of its associated with selective 
pregnancy termination. Whilst unequivocally supporting a 
woman's right to make an informed choice about her own 
body and life, Rosie queried whether hemophilia was suffi-
cient grounds for what she described as such a “drastic” in-
tervention, and her views were further reinforced (along with 
those of four other participants) by her experiences of both 
the implicit and explicit pressures she reported experiencing 
at the hands of clinicians to at least consider genetic testing 
and possible termination during her pregnancies;
….the consultant was very keen for us to have 
an amniocentesis. What he couldn't do though 
was convince me of the benefit compared to the 
cost on that, because at no point … Harvey hav-
ing haemophilia would in no way have led to 
us terminating the pregnancy and therefore we 
were struggling to find a benefit to offset that 
risk because you know, it was up to a 3% risk 
[of miscarriage]. Well you know, that's one in 
30 and you know you wouldn't … I mean you 
wouldn't send a kid to school if you knew one 
of them in the class wasn't going to come home 
would you? You know, so there was no benefit 
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for us, so I didn't know why, you know, there 
was no reason in my mind to take that test.
For Rosie, her unwillingness to terminate any affected preg-
nancy counter‐balanced any argument in favor of submitting to 
an invasive test that carried the risk of fetal loss. Indeed, when 
considering the possibility of a population level prenatal ge-
netic screening programme for hemophilia, this dislocation of 
screening practices from the next steps in the process (namely 
prenatal diagnosis and potentially also pregnancy termination) 
underpinned the majority of participants’ views on screening. 
By separating screening from its association with selective 
abortion, participants instead justified support for the practice 
on the grounds of the physical and psychological preparation of 
the parents and the practical/clinical preparations necessary for 
the birth of a boy with hemophilia.
Unlike Rosie, Karen (aged 38) came to her interview 
with the least prior experience of hemophilia of all the 
participants in the qualitative phase. Her son, Benji, was 
eight months old at the time of interview and had been 
diagnosed with hemophilia just two months previously, 
following significant bleeds into his legs from routine 
childhood vaccinations. Whilst Karen was clear in her 
support of both preconception and prenatal screening for 
hemophilia, this was presented, rather than a way of pre-
venting lives with hemophilia, but instead as a means of 
protecting and caring for both carrier mothers and boys 
with hemophilia.
T A B L E  6  Response summaries for questions assessing views on preconception genetic screening (PCGS). 
Question
F vs. AwD (all) F (Hem A vs. B) AwD (Hem A vs. B)
Hem A 
(F vs. 
AwD)
Hem B 
(F vs. 
AwD)
p‐Value
Identifying hemophilia in pregnancy will 
inevitably lead to less people with hemophilia 
coming into the world who could have lived 
fulfilling lives
0.57 0.66 0.98 0.54 0.99
Screening for hemophilia in pregnancy will 
enable everyone to make informed decisions 
about whether or not to bring a child with 
bleeding disorders into the world
0.07* 0.65 0.86 0.12 0.39
Screening for hemophilia in pregnancy will 
prevent unnecessary suffering
0.68 0.68 0.73 0.61 0.56
Screening for hemophilia in pregnancy will raise 
awareness of the condition in the general 
population
0.81 0.37 0.81 0.58 0.53
It would be a loss to society to have less people 
with hemophilia coming into the world
0.08* 0.86 0.29 0.21 0.25
It would be hard for pregnant women and their 
partners to refuse screening for hemophilia in 
pregnancy
0.81 0.36 0.37 0.79 0.99
Screening for hemophilia in pregnancy is still 
useful even if they can’t tell you how severely 
affected the child would be
0.11 0.81 0.53 0.25 0.25
Termination of pregnancies affected by hemo-
philia is unfortunately necessary if we are to 
make sure that the condition is eliminated
0.35 0.78 0.49 0.41 0.69
Prenatal screening for hemophilia is useful, but 
only insofar as it can aid and preparation for the 
birth of a boy with hemophilia, not for the 
consideration of termination (abortion)
0.14 0.41 0.08* 0.12 0.99
I would support a prenatal screening programme 
for hemophilia
0.73 0.85 0.94 0.81 0.78
Note. A) Response breakdowns are shown for family sub‐groups (all, hemophilia A and hemophilia B) and adults with disease sub‐groups (all, hemophilia A and hemo-
philia B). B) Response distributions were compared using chi‐squared analysis (p‐value; *p = 0.05‐0.1).
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Yeah, I certainly wouldn't terminate [for hae-
mophilia] …. Obviously it's devastating because 
you'd never want that for your child, but there's 
great support out there and it can be managed 
pretty well and in time it will get easier. But if 
they're doing HIV screening at the point of mid-
wifery booking in, I don't see why they can't do 
haemophilia screenings at that point. Because 
I was … I had to go on heparin [during preg-
nancy with Benji], a blood thinning drug and 
T A B L E  7  Age, sex, and relationship to bleeding disorder of qualitative interview participants
Pseudonym Age Sex
Condition in 
Family Parent?
Number of Children with a 
Bleeding Disorder
Nature of experience with Bleeding 
Disorder
Kathy 66 F VWB and 
hemophilia
✓ 0 Kathy has von Willebrand's Disease. 
Father had hemophilia. Grandmother 
to two boys with hemophilia
Rosie 38 F Hemophilia ✓ 1 Father and son have hemophilia
Kiara 26 F Hemophilia × 0 Sister of two brothers with hemophilia 
& sister of female carrier. Own carrier 
status unknown.
       
Sophie 45 F Hemophilia ✓ 2 Mother of two sons with hemophilia.
Karen 38 F Hemophilia ✓ 1 Son has hemophilia
Jenny 46 F Hemophilia ✓ 1 Brother and son have hemophilia
Megan 40 F Hemophilia ✓ 1 Brother and son have hemophilia
Ellie 23 F VWB × 0 Has Von Willebrand's Disease, as does 
mother
Charlotte 52 F VWB ✓ 1 Has Von Willebrand's Disease, as does 
daughter (Ellie)
Sarah 41 F Hemophilia 
(severe)
✓ 0 Husband has severe hemophilia, 
daughter is a carrier
Chloe 39 F Hemophilia B 
(severe)
✓ 1 Son diagnosed with severe hemophilia 
B
Harriet 37 F Hemophilia A 
(severe)
✓ 2 Nephew and two sons have severe 
hemophilia A
Tim 51 M Hemophilia A 
(severe)
× 0 Has severe hemophilia A
Mark 46 M Factor XIII 
deficiency
✓ 0 Has Factor XIII deficiency
Valerie 64 F Hemophilia 
(mild)
✓ 0 Husband has mild hemophilia, two 
daughters are obligate carriers, four 
grandsons have hemophilia
John 83 M Hemophilia 
(mild)
✓ 0 Has mild hemophilia, two carrier 
daughters and four grandsons have 
hemophilia (husband of Valerie)
Emma 38 F Hemophilia ✓ 1 Father has hemophilia, son has 
hemophilia, and three nephews have 
hemophilia
Alex 57 M Hemophilia ✓ 0 Has hemophilia, brother had hemo-
philia but died from hepatitis infection
Dylan 21 M Hemophilia × 0 Hemophilia & brother
Arun 28 M Hemophilia × 0 Has hemophilia
Jo 35 F Hemophilia B × 0 Father has hemophilia B, nephew has 
hemophilia B
Michael 71 M Hemophilia ✓ 0 Has hemophilia
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obviously had I been under the haematology 
team and had I been screened for it [haemo-
philia carrier status] they wouldn't have proba-
bly given me it [the heparin], or at least I'd have 
been very closely monitored. I don't know if 
that's caused any damage to him [Benji]. I'd like 
to think it hasn't and he was protected by my 
placenta, but he was on blood thinning and ob-
viously he was born by C‐section, so there could 
have been massive complications. So that would 
have been really helpful…. So yes, I do think it's 
very important to have screening.
For Karen, rather than a means of eradicating hemophilia 
(a response to prenatal testing frequently reported in the litera-
ture), she viewed prenatal screening as a means to source infor-
mation that could actually be used to protect and preserve lives 
affected by hemophilia. This interpretation of the potential uses 
of prenatal screening were widely reflective of the attitudes of 
other participants in the study, as well as being reflected in the 
quantitative data. A small sub‐set of participants, however, all of 
whom had hemophilia themselves, expressed more conflicted 
views about screening, on the one hand viewing screening as 
an important source of information, but also as potentially lead-
ing to impossible decisions that the general public may be ill‐
equipped to make.
Tim was 51 years old at the time of his interview, and was 
diagnosed with hemophilia A in the early 1970s when he was 
three years old. Tim described the negative reaction of his 
family to the diagnosis, in particular the guilt, shame, and 
stigma experienced by his parents, which appeared to have 
been absorbed, at least in part, by Tim and his sister Anita, 
both of whom had made a commitment from an early age 
not to reproduce and risk passing on the condition. This view 
was reinforced when Tim contracted both Hepatitis B and C 
in the 1980s, and at the time of interview, Tim also believed 
he could be HIV positive. His decision never marry or have 
children, whilst ultimately contributing to the breakdown 
of Tim's relationship, was nevertheless one he described as 
standing by as an adult. For Tim, population screening for 
hemophilia is important, not only because it has the poten-
tial to prevent children being born with hemophilia, but also 
because it allows parents to avoid becoming what he termed 
“hemophilia parents”, a job which he thought not everyone is 
well suited to take on:
I would say … and this is looking back onto 
my parents as well—it's always much harder 
to be the parent of a haemophiliac than to be 
the haemophiliac themselves. As a parent you 
have to deal with all the guilt and the care of the 
child, whatever that may involve and you don't 
know…. And most people can't fully take on 
board what that means anyway. Like I said pre-
viously, no matter what you can say to people, 
until you physically experience it, you've got no 
sense of proportion or what it actually means 
in reality. You know, I have been asked ques-
tions by various people about what haemophilia 
is really like, you know, but we're all different, 
that's the problem, and how I react and manage 
my haemophilia is completely different to how 
someone else may do. So yeah it's [screening] 
giving people decisions, but not necessarily the 
tools to actually make them.
By highlighting both the importance, but also the limits 
of the information that can be gathered from a screening 
test for hemophilia, Tim's perspective was typical of some 
of the older men with hemophilia within the sample who 
had experienced both the physical harms, but also the in-
tensely damaging social stigma of having receiving con-
taminated blood products in the 1980s and 90s, which for 
Tim, and other participants, had resulted in severe health 
complications, social stigma and bullying (Mark; John; 
Michael). For hemophiliac men such as Tim, Mark, John, 
and Michael (see Table 7) whose life experiences with he-
mophilia drew little resemblance to those of younger gen-
erations with hemophilia described by Rosie and Karen 
(largely due to the introduction of prophylaxis from a 
young age), the possibility of being able to predict life 
quality and experiences with hemophilia from the results 
of genetic tests was viewed as unrealistic, even as they sup-
ported the basic premise of screening and early identifica-
tion of hemophilia.
4 |  DISCUSSION
This paper, to the best of our knowledge, is the largest and 
most in‐depth study of attitudes toward hemophilia screen-
ing and prevention amongst families and adults living with 
hemophilia ever to be conducted. Within a broader cultural 
and technological context whereby genomic technologies 
are becoming both more efficient and more accessible than 
ever before, and yet paradoxically people with genetic disor-
ders such as hemophilia are simultaneously living longer and 
more fulfilling lives (Cassis et al., 2012) , the reflections of 
affected adults and their families will only become increas-
ingly important. Indeed, as a society, we are facing signifi-
cant decisions about which conditions are considered serious 
enough to warrant their prevention (or even gradual elimi-
nation) through population level genomic screening and, as 
such, the accounts of people living with genetic disease—the 
best “experts” on their condition are critical to these deci-
sions (Asch & Wasserman, 2014; Korngiebel et al., 2016; 
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Petersen, 2006; Roadhouse et al., 2018; Wertz & Knoppers, 
2002).
Indeed, there are a range of potential impacts that pop-
ulation‐level genomic screening could have that are unique 
to affected families and adults, that warrant their inclusion 
as stakeholders in screening debates. Such impacts include 
the possible reduction in research funding or availability of 
treatments, reductions in peer‐to‐peer support as well as the 
potential for increased stigmatization as the public profile of 
the disorder shifts to a “preventable” disorder.
This study has revealed that families and adults affected 
by hemophilia are largely aware of the range of possible im-
pacts for them should screening be introduced and these con-
cerns were key to explaining why support for preconception 
and prenatal genetic screening were markedly lower among 
families and adults living with hemophilia than has been ob-
served in relation to other genetic conditions, such as Spinal 
Muscular Atrophy (Boardman et al., 2016). Indeed, the tran-
sition of hemophilia from a condition that was fatal in child-
hood in the 1970s, to one that is largely treatable, is likely to 
have influenced families’ views on the necessity and value of 
screening for the disorder.
Alongside shifts in the treatability of hemophilia, there 
have been concomitant and significant changes in the way 
in which hemophilia families both access, and make use of, 
prenatal diagnosis in recent years. The widespread introduc-
tion of NIPT has made fetal sex identification both more re-
liable and accessible, and at earlier points in pregnancy than 
was previously possible (Hill et al., 2012). The introduction 
of this technology, by “filtering out” female fetuses who 
will never develop hemophilia, has played a pivotal role in 
the sharp decline of invasive diagnoses for pregnant carrier 
women. However, along with a decline in accessing prenatal 
diagnosis, it has also been observed that rates of pregnancy 
termination when hemophilia is detected in this way, have 
also been steadily declining, as families increasingly access 
the test in order to make the birth as safe as possible for a 
hemophiliac baby, rather than to terminate the pregnancy 
(Mårtensson et al., 2014).
This trend toward testing for information for preparation 
purposes rather than to avoid genetic disease was reflected 
clearly in both our qualitative and quantitative data on screen-
ing, and may explain why PNGS garnered slightly more 
support from the cohort than PCGS (59% vs. 57%), despite 
the closer alignment of PNGS with pregnancy terminations. 
Indeed, whilst previous research has demonstrated a wide-
spread correlation between accessing prenatal diagnosis and 
intentions to end affected pregnancies, this study suggests 
that the reverse is true for families and adults living with he-
mophilia. Confirming the findings of other studies explor-
ing uptake of screening and pregnancy termination amongst 
families affected by genetic disease (Ryan, Miedzybrodzka, 
Fraser, & Hall, 2003), the findings of this study suggest that 
rather than a means of eliminating the condition, PNGS was 
viewed primarily as a means of supporting, or even preserv-
ing the lives of boys with hemophilia and carrier women 
(e.g., Karen). Indeed, 69% of the sample agreed that PNGS 
should be used exclusively for information purposes, and 
90% disagreed on principle with the use of pregnancy ter-
mination to prevent hemophilia. Indeed, it was the implicit 
and explicit links between PNGS and pregnancy termination 
that led participants with extensive prior knowledge of hemo-
philia to reject PNGS (e.g., Rosie).
Unlike previous studies of the views of families and adults 
with genetic disease toward reproductive genetics (Boardman 
et al., 2016; Maxwell et al., 2011; Raspberry & Skinner, 
2011), this study also highlights the strong degree of agree-
ment in reproductive attitudes between adults with hemo-
philia and their family members. Furthermore, this agreement 
was retained even across the different types and severities of 
hemophilia. Despite their very different ways of knowing 
and experiencing hemophilia, both families and adults were 
largely united, not only in their support of screening, but also 
their disapproval of its uses for termination purposes. This 
finding underscores the centrality of direct lived experience 
to reproductive views and decisions, and the importance of 
considering the experiential knowledge of family members 
as well as those diagnosed with genetic disease, particularly 
parents and siblings whose lives are often fundamentally al-
tered, albeit in different ways, by a hemophilia diagnosis in 
the family (Cassis et al., 2012; von der Lippe, Frich, Harris, 
& Solbrække, 2017).
The only key area of divergence between participant 
groups related to perceptions of carrier status stigmatiza-
tion, where participants diagnosed with hemophilia A were 
found to be more likely than any other group to perceive 
stigma around carrier status. Given that the majority of 
adults diagnosed with hemophilia A who participated in 
the survey reported either having been exposed to, or hav-
ing contracted, a blood born virus (most commonly HIV 
or Hepatitis B/C) in the 1980s or 90s, it is likely that ex-
periences of social stigma related to contaminated blood 
were transferred into attitudes toward carrier identification. 
In addition to the possibility of blood contamination, the 
relative severity of hemophilia A and associated treatments 
may have also contributed to these differences, with re-
search highlighting that most men with hemophilia are re-
luctant to disclose their condition beyond close family and 
friends (Cassis et al., 2012).
Finally, despite the fact that the majority of the sam-
ple supported the underlying principles of both PCGS 
and PNGS, albeit insofar as they can provide information 
and aid preparation, it is noteworthy that most (61%) si-
multaneously also agreed that a decline in people born 
with hemophilia would not be a loss to society. The in-
herent tensions between these two value statements, a 
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rejection of pregnancy terminations for hemophilia on 
the one hand, but also a belief that the continued exis-
tence of hemophilia does not contribute anything to so-
ciety worth preserving on the other, may at first glance 
appear contradictory, but in fact strikes at the very heart 
of the key issue facing reproductive genomic medicine 
today; namely, the conflict between preventing diseases 
from coming into existence, and preventing the people 
who would have those diseases from coming into exis-
tence. It is this distinction that has informed much of the 
disability rights responses to prenatal screening, testing, 
and pregnancy termination and plagued the accounts of 
parents of genetically disabled children considering fu-
ture pregnancies (Kelly, 2009). Through their responses 
to both the survey and in‐depth interviews, it appeared 
that families and adults with hemophilia were largely 
able to disentangle their views about hemophilia from 
their views about people with hemophilia, which contrib-
uted to these seeming contradictions.
Indeed, the relationship between genetic disorders and 
personal/social identity is emerging as an important fac-
tor in recent analyses of the responses of disabled peo-
ple to advances in genetic medicine more widely (Asch 
& Wasserman, 2014) and is likely to only become more 
significant overtime. Technologies such as genome edit-
ing suggest a future in which it may be possible to focus 
ameliorative responses to genetic disease solely on the dis-
ease causing genetic variant, whilst preserving the life of 
the would‐have‐been disabled fetus. Future research may 
usefully explore this role of identity politics within the re-
sponses of genetically disabled adults and their families to-
ward population level genetic screening, as well as the types 
of experience with genetic disease that lend themselves to 
support or nonsupport of screening and disease prevention, 
particularly as they relate to pregnancy termination.
4.1 | Strengths and weaknesses
A key strength of this study is the depth and breadth of data 
collated. However, due to confidentiality and data protection 
constraints, no identifiable data were asked of individuals who 
participated in the Haemophilia Screening Survey (UK), in-
cluding IP address (where the survey was completed online). 
This meant that there was no mechanism in place to prevent 
an individual completing multiple surveys. Moreover, there 
was no way to verify that the participant fitted the inclusion 
criteria. Participants were furthermore accessed through a na-
tional support group rather than hemotology clinics, which 
may have introduced bias. Moreover, given the relatively 
high incidence of hemophilia A, people with hemophilia B 
were under‐represented in the sample, although their num-
bers were broadly reflective of the prevalence of these sub‐
types of hemophilia within the UK population.
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